SHYNDEC(SH:600420) Ge Long Hui A P P·2025-09-12 08:46Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (国药容生), received approval from the National Medical Products Administration for a supplemental application regarding sodium bicarbonate injection, allowing for an increase in specifications and passing the consistency evaluation of generic drug quality and efficacy [1]. Group 1 - The sodium bicarbonate injection is classified as an antacid and is indicated for the treatment of metabolic acidosis [1]. - It is also used for the prevention of uric acid kidney stones, reducing the nephrotoxicity of sulfonamide drugs, and preventing hemoglobin deposition in renal tubules during acute hemolysis [1]. - Additionally, intravenous administration of this injection has non-specific therapeutic effects for certain drug poisonings, such as barbiturates, salicylates, and methanol [1].